ArticleFrontiers in immunology2021
Transcriptome Analysis of Peripheral Blood Mononuclear Cells Reveals Distinct Immune Response in Asymptomatic and Re-Detectable Positive COVID-19 Patients.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Peripheral immune progression to long COVID is associated with mitochondrial gene transcription: A meta-analysis.Mitochondrion · 2025Pooled it
- The genetic associations of COVID-19 on genitourinary symptoms.Frontiers in immunology · 2023Pooled it
- Multicohort transcriptome analysis of whole blood identifies robust human response signatures in Plasmodium falciparum infections.Malaria journal · 2022Pooled it
- Divergent immunometabolic landscapes of chicken and swan goose identify SERPINF2 as a novel restriction factor for influenza A virus.Virology journal · 2026Article
- Transcriptomic profiling reveals immune signatures associated with potential COVID-19 susceptibility and a predictive framework in a Chinese cohort.Frontiers in immunology · 2026Article
- Identification and evaluation of candidate COVID-19 critical genes and medicinal drugs related to plasma cells.BMC infectious diseases · 2024Article
- Systems-wide view of host-pathogen interactions across COVID-19 severities using integrated omics analysis.iScience · 2024Article
- Type I Interferon Pathway-Related Hub Genes as a Potential Therapeutic Target for SARS-CoV-2 Omicron Variant-Induced Symptoms.Microorganisms · 2023Article
- Transcriptome-based analysis of human peripheral blood reveals regulators of immune response in different viral infections.Frontiers in immunology · 2023Article
- Article
- Clinical and Gene Features of SARS-CoV-2-Positive Recurrence in Patients Recovered From COVID-19.Frontiers in molecular biosciences · 2022Article
- Bioinformatics analysis of potential pathogenesis and risk genes of immunoinflammation-promoted renal injury in severe COVID-19.Frontiers in immunology · 2022Article
- Tracing the cell-type-specific modules of immune responses during COVID-19 progression using scDisProcema.Computational and structural biotechnology journal · 2022Article
- T-Cell Repertoire Characteristics of Asymptomatic and Re-Detectable Positive COVID-19 Patients.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The existence of asymptomatic and re-detectable positive coronavirus disease 2019 (COVID-19) patients presents the disease control challenges of COVID-19. Most studies on immune responses in COVID-19 have focused on moderately or severely symptomatic patients; however, little is known about the immune response in asymptomatic and re-detectable positive (RP) patients. Here we performed a comprehensive analysis of the transcriptomic profiles of peripheral blood mononuclear cells (PBMCs) from 48 COVID-19 patients which included 8 asymptomatic, 13 symptomatic, 15 recovered and 12 RP patients. The weighted gene co-expression network analysis (WGCNA) identified six co-expression modules, of which the turquoise module was positively correlated with the asymptomatic, symptomatic, and recovered COVID-19 patients. The red module positively correlated with symptomatic patients only and the blue and brown modules positively correlated with the RP patients. The analysis by single sample gene set enrichment analysis (ssGSEA) revealed a lower level of IFN response and complement activation in the asymptomatic patients compared with the symptomatic, indicating a weaker immune response of the PBMCs in the asymptomatic patients. In addition, gene set enrichment analysis (GSEA) analysis showed the enrichment of TNFα/NF-κB and influenza infection in the RP patients compared with the recovered patients, indicating a hyper-inflammatory immune response in the PBMC of RP patients. Thus our findings could extend our understanding of host immune response during the progression of COVID-19 disease and assist clinical management and the immunotherapy development for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.